Marshall Wace, LLP Liquidia Corp Call Options Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LQDA
# of Institutions
171Shares Held
44.3MCall Options Held
1.55MPut Options Held
1.52M-
Patient Square Capital LP Menlo Park, CA7.18MShares$81.2 Million26.66% of portfolio
-
Black Rock Inc. New York, NY4.24MShares$48 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$38.9 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.29MShares$37.2 Million0.17% of portfolio
-
Findell Capital Management LLC New York, NY3.19MShares$36.1 Million16.08% of portfolio
About Liquidia Corp
- Ticker LQDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,362,300
- Market Cap $728M
- Description
- Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...